A journey of hope: lessons learned from studies on rare diseases and orphan drugs
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
: Rare diseases are frequently life‐threatening or chronically debilitating and the impact on the quality of life of affected patients and their family members is thus significant. However, drug development for these conditions has been limited by a lack of understanding of the underlying mechanisms of disease and the relative unavailability of subjects for clinical trials, as well as the prohibitive cost of investing in a novel pharmaceutical agent with poor market potential. Nevertheless, the introduction of Orphan Drug legislations has provided important incentives for the development of orphan drugs (i.e. drugs that have been abandoned or ‘orphaned’ by major drug companies). Moreover, recent studies on rare diseases, including inherited immunodeficiencies and metabolic disorders, have served not only to alleviate the plight of patients with rare diseases, but also yielded valuable information on biological processes of relevance for other, more common conditions. These lessons, along with the crucial importance of cooperation between academic institutions, pharmaceutical companies, patient advocacy groups and society in the elucidation of rare diseases, are highlighted in the present review.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
IMMUNOLOGICAL RECONSTITUTION OF SEX-LINKED LYMPHOPENIC IMMUNOLOGICAL DEFICIENCY
Gatti, R., Meuwissen, H., Allen, H., Hong, R., & Good, R. (1968) · The Lancet · doi:10.1016/s0140-6736(68)92673-1 · Cited by 1,018
Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase
LINDSTEDT, S. (1992) · The Lancet · doi:10.1016/0140-6736(92)92685-9 · Cited by 631
Tyrosinaemia type I and NTBC (2‐(2‐nitro‐4‐trifluoromethylbenzoyl)‐1,3‐cyclohexanedione)
Holme, E., & Lindstedt, S. (1998) · Journal of Inherited Metabolic Disease · doi:10.1023/a:1005410820201 · Cited by 264
The pathophysiology and treatment of hereditary tyrosinemia type 1
Grompe, M. (2001) · Seminars in Liver Disease · doi:10.1055/s-2001-19035 · Cited by 167
Cited by
Lessons Learnt from Assembling Screening Libraries for Drug Discovery for Neglected Diseases
Brenk, R., Schipani, A., James, D., Krasowski, A., Gilbert, I. H., Frearson, J., & Wyatt, P. G. (2008) · ChemMedChem · doi:10.1002/cmdc.200700139 · Cited by 709
Why rare diseases are an important medical and social issue
Schieppati, A., Henter, J.-I., Daina, E., & Aperia, A. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60872-7 · Cited by 619
Self-citationLiving with a rare disorder: a systematic review of the qualitative literature
von der Lippe, C., Diesen, P. S., & Feragen, K. B. (2017) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.315 · Cited by 378
“One suggested way in improving the situation of people with rare conditions is to increase the awareness of rare diseases throughout society (Wastfelt et al. 2006; Dodge et al. 2011), and more specifically within the healthcare system.”
BackgroundThree‑dimensional cell culture: A powerful tool in tumor research and drug discovery (Review)
Lv, D., Hu, Z., Lu, L., Lu, H., & Xu, X. (2017) · Oncology Letters · doi:10.3892/ol.2017.7134 · Cited by 337
Drug repositioning for orphan diseases
Sardana, D., Zhu, C., Zhang, M., Gudivada, R. C., Yang, L., & Jegga, A. G. (2011) · Briefings in Bioinformatics · doi:10.1093/bib/bbr021 · Cited by 228
Considerations for AI fairness for people with disabilities
Trewin, S., Basson, S., Muller, M., Branham, S., Treviranus, J., Gruen, D., Hebert, D., Lyckowski, N., & Manser, E. (2019) · AI Matters · doi:10.1145/3362077.3362086 · Cited by 143
Children with a rare congenital genetic disorder: a systematic review of parent experiences
von der Lippe, C., Neteland, I., & Feragen, K. B. (2022) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-022-02525-0 · Cited by 94
“Increased awareness of rare disorders throughout society, and within the health care system, is one suggested action to improve the situation of people with rare disorders [20, 21].”
BackgroundChen, B., & Altman, R. B. (2017) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-017-0614-4 · Cited by 28
“Many rare diseases have been linked to genetic abnormalities, and next-generation sequencing has accelerated our ability to make such links [3].”
BackgroundSchott, A. F., Welch, J. J., Verschraegen, C. F., & Kurzrock, R. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.07.010 · Cited by 20
Nicoloro SantaBarbara, J., & Lobel, M. (2022) · Journal of Health Psychology · doi:10.1177/13591053211014583 · Cited by 17
“Although there is considerable psychosocial research on common chronic illnesses such as rheumatoid arthritis and multiple sclerosis, rare diseases such as MCAS have historically received little attention from psychological science (Heemstra et al., 2009; Litterman et al., 2014; Wästfelt et al., 2006).”
BackgroundSchlump, J.-U., Mayatepek, E., & Spiekerkoetter, U. (2010) · European Journal of Pediatrics · doi:10.1007/s00431-009-1074-1 · Cited by 13
Metadata
- Authors
- WÄSTFELT, M., FADEEL, B., & HENTER, J. ‐.
- Venue
- Journal of Internal Medicine
- Publisher
- Wiley
- Published
- 2006-06-15
- Volume
- 260
- Issue
- 1
- Pages
- 1-10
- ISSN
- 0954-6820 (ISSN-L)
- 1365-2796
- OpenAlex
- W2116801544
- Cited by
- 184
- References
- 5
- FWCI
- 13.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.